

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

MEDA PHARMACEUTICALS INC. and)	
CIPLA LTD.,)	
)	
Plaintiffs,)	
)	C.A. No. 14-1453-LPS
v.)	
)	
APOTEX INC. and APOTEX CORP.,)	
)	
Defendants.)	

**MEDA PHARMACEUTICALS INC. AND CIPLA LTD.’S NOTICE OF DEPOSITION
OF APOTEX INC. AND APOTEX CORP.’S PURSUANT TO FED. R. CIV. P. 30(b)(6)**

PLEASE TAKE NOTICE that Plaintiffs Meda Pharmaceuticals Inc. (“Meda”) and Cipla Ltd. (“Cipla”) (collectively, “Plaintiffs”) by their counsel will take the testimony by deposition upon oral examination of Defendants Apotex Inc. and Apotex Corp. (collectively, “Apotex” or “Defendants”) pursuant to Rule 30(b)(6) of the Federal Rules of Civil Procedure.

The deposition will begin at 9:00 a.m. on January 29, 2016 at the offices of STERNE KESSLER GOLDSTEIN & FOX P.L.L.C., 1100 New York Avenue, N.W., Washington, D.C. 20005, or at such other time and place as may be agreed upon by counsel. The examination will be taken before a Notary Public or other person authorized to administer oaths pursuant to Rule 28 of the Federal Rules of Civil Procedure, and will continue from day to day until completed. The testimony at the deposition will be recorded by videographic, stenographic, audio, audiovisual, and/or real-time computer means.

Pursuant to Rule 30(b)(6), Defendants shall designate one or more officers, directors, managing agents, or other persons who consent and are knowledgeable to testify on its behalf with respect to each of the subject matters set forth in attached Schedule A. Defendants are

requested to provide Plaintiffs' counsel with written notice, at least ten (10) business days in advance of the deposition, of the name and title of each witness who will testify on behalf of Defendants and the particular topic(s) set forth in Schedule A as to which each such witness will testify.

Pursuant to Rule 30(b)(2) of the Federal Rules of Civil Procedure, Defendants are hereby requested to produce at or before the time of the deposition, any and all documents and things that in any way refer to or concern any of the topics set forth in the attached Schedule A that have not previously been produced to Plaintiffs in this action. Plaintiffs reserve the right to continue this deposition should Defendants fail to produce such documents and things at or before the time of the deposition.

If counsel for Defendants have any questions regarding this Notice, you are invited to contact counsel for Plaintiffs to discuss the matter.

ASHBY & GEDDES

/s/ John G. Day

Of Counsel:

H. Keeto Sabharwal
Dennies Varughese
Uma N. Everett
Rami Bardenstein
Dallin Glenn
Josephine J. Kim
STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
1100 New York Ave., N.W., Suite 800
Washington, DC 20005-3934
(202) 371-2600

Steven J. Balick (#2114)
John G. Day (#2403)
Andrew C. Mayo (#5207)
500 Delaware Ave., 8th Floor
P.O. Box 1150
Wilmington, DE 19899
(302) 654-1888
sbalick@ashby-geddes.com
jday@ashby-geddes.com
amayo@ashby-geddes.com

*Attorneys for Plaintiffs
Meda Pharmaceuticals Inc. and Cipla Ltd.*

Dated: December 30, 2015

SCHEDULE A

DEFINITIONS

The following definitions shall apply:

1. The terms “Apotex,” “Defendants,” “you” and “your” mean Apotex Inc., any of its predecessors, subsidiaries (including Apotex Corp.), domestic or foreign divisions, departments, parents, affiliates, present or former officers, directors, employees, agents, representatives, entities acting in concert, joint-venture, or partnership relationship with you, and others acting on your behalf.
2. The term “Meda” means Meda Pharmaceuticals Inc. and any of their predecessors, domestic or foreign divisions, departments, subsidiaries, parents or affiliates.
3. The term “Cipla” means Cipla Ltd. and any of their predecessors, domestic or foreign divisions, departments, subsidiaries, parents or affiliates.
4. The term “Plaintiffs” means Meda Pharmaceuticals Inc. and Cipla Ltd. and any of their predecessors, domestic or foreign divisions, departments, subsidiaries, parents or affiliates.
5. The term “present action,” “this action,” “this lawsuit,” or “this litigation” means *Meda Pharmaceuticals Inc., et al. v. Apotex Inc., et al.*, C.A. No. 14-cv-1453-LPS (D. Del.).
6. The term “Patents-in-Suit” refers to U.S. Patent Nos. 8,163,723 and 8,168,620 and all applications that led to their issuance.
7. The term “Asserted Claims” refers to the claims of the Patents-in-Suit identified in Plaintiffs’ July 13, 2015 disclosure of asserted claims, including claims 1-4, 7, 8, 10-18, and 20-28 of the ’723 patent and claims 1-13, 15-18, 21, 22, 24-26, 28, 29, 31, 33, 35-47 of the ’620 patent.

8. The terms “infringe” and “infringement” mean direct infringement, contributory infringement, inducement of infringement, literal infringement, and infringement under the doctrine of equivalents. *See* 35 U.S.C. § 271.

9. “NDA” means “New Drug Application” as defined under 21 U.S.C. § 355(b) *et seq.*

10. “ANDA” means “Abbreviated New Drug Application,” as defined under 21 U.S.C. § 355(j) *et seq.*

11. “Orange Book” means Approved Drug Products with Therapeutic Equivalence Evaluations, which is published by the Secretary of the U.S. Department of Health and Human Services pursuant to 21 U.S.C. §§ 355(b)(1) and (c)(2).

12. “Paragraph IV Certification(s)” means a certification made by an ANDA filer that it believes a patent is invalid, unenforceable, or will not be infringed by the manufacture, use, or sale of the generic drug for which the ANDA is submitted, made pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV) and 21 C.F.R. § 314.94(a)(12)(i)(A)(4).

13. “Paragraph IV Notice(s)” means a notice sent pursuant to 21 U.S.C. § 355(j)(2)(B) and 21 C.F.R. § 314.95 to the named owner of the patents listed in the Orange Book and/or the holder of the NDA for the reference listed drug, which provides the legal and factual bases for the ANDA filer’s belief that the listed patents are invalid or not infringed by a proposed generic product.

14. “Dymista[®]” is the azelastine and fluticasone combination nasal spray product described in NDA No. 202236.

15. “Apotex’s Nasal Spray” means the products and formulation(s) described in Apotex’s ANDA No. 207712 for which Apotex is seeking FDA approval for any indication.

16. The term “Prior Art” means any subject matter encompassed by 35 U.S.C. § 103 and each and every subsection of 35 U.S.C. § 102.

17. The term “person” means any individual, corporation, partnership, sole proprietorship, firm, board, joint venture, association, agency, authority, commission, or other entity.

18. The term “document(s)” is defined broadly to be given the full scope of that term contemplated by the Federal Rules of Civil Procedure, and the Federal Rules of Evidence, and includes all non-identical copies of a document, all drafts of final documents, all other written, typed, printed, recorded or graphically portrayed matter in any form or embodiment, and all other data compilations from which information can be obtained and translated if necessary, that are or have been in your actual or constructive custody or control, regardless of the medium on which they are produced, reproduced, stored (including computer programs and files containing any requested information), and any recording or writing, as these terms are defined in Federal Rule of Evidence 1001. Any document bearing marks, including initials, stamped initials, comments, or notations not part of the original text or photographic reproduction thereof, is a separate document.

19. The term “communication(s)” means all written, electronic, oral, telephonic, or other inquiries, dialogues, conversations, interviews, correspondence, consultations, negotiations, agreements, understandings, meetings, letters, notes, telegrams, advertisements, computer mail, email, and all other documents evidencing any verbal or nonverbal interaction between persons and entities.

20. The term “thing(s)” shall be construed under the broadest possible construction under the Federal Rules of Civil Procedure.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.